* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WXIBF vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Buyback Yield % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a Buyback Yield % of 1.01 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #51 out of 741 companies in the Biotechnology industry, placing it in the top 6.9%.
Is WuXi Biologics (Cayman)'s Buyback Yield % too high?
WuXi Biologics (Cayman)'s current Buyback Yield % is 1.01. Based on the distribution chart, WuXi Biologics (Cayman) ranks #51 out of 741 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #51 out of 741 companies for Buyback Yield %. This places WuXi Biologics (Cayman) in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Buyback Yield % is 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.12, compared to a current price of $4.77 — trading 6.9% below its estimated fair value. The current Buyback Yield % is 1.01. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Buyback Yield % is 1.01 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.77 is trading 6.9% below its estimated GF Value™ of $5.12.
GuruFocus considers WuXi Biologics (Cayman) to be Fairly Valued.
Key valuation signals for WXIBF:
Buyback Yield %: 1.01
GF Value™: $5.12 vs. price of $4.77 (6.9% below fair value)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
